The current definition of leukodystrophy is ‘a genetic disorder primarily affecting central nervous system (brain or spinal cord) white matter. White matter is a substance deep in the brain that affects learning and brain functions. It contains nerve fibres (axons) that have a covering called called myelin (the myelin sheath), which appears white in laboratory conditions. Leukodystrophy affects males and females of all ages and ethnic backgrounds, most notably children.

Leukodystrophies may also be referred to as Inherited (or genetic) White Matter Disorders (IWMDs) meaning that the affected person has been born with a genetic abnormality that causes the disease. This may happen because a genetic abnormality occurs for the first time in the affected person at conception, or may have been inherited from one or both parents who “carry” the genetic abnormality. To understand more about the basics of genetics and inheritance, you can view this video from the European Reference Network (ERN).

Advances in the understanding of leukodystrophy

The definition of ‘leukodystrophy’ has changed over time, as a result of improved in understanding of the disorders. The word “leukodystrophy” is an old word that was coined to describe a genetic disease of the white matter of the brain. The term comes from the Greek language – leuko “white”, dys “abnormal”, and trophy “thrive or grow”. Put together, this describes a deteriorative process of the white matter in the brain.

Before the gene abnormalities that cause leukodystrophies were identified, the term “leukodystrophy” referred to a genetic disease of the white matter of the brain usually following a deteriorating or degenerative course. For many years it was thought that leukodystrophies were primarily diseases of myelin or myelination.

In the past two decades there has been a revolution in the understanding of the causes of white matter diseases with the identification of the gene abnormalities that cause the diseases to develop. This has led to increased understanding of the many different ways in which the white matter of the brain may be affected and a recognition that these were not exclusively diseases of myelin. It was also recognised that not all leukodystrophies followed a degenerative course.

How many leukodystrophies are there?

There are over 100 identified leukodystrophies, with some so rare they are yet to be named. The majority of these conditions cause progressive neurodegeneration and are largely untreatable. Individual conditions and their symptoms are described here.

Alex TLC focuses on the similarities between these conditions, bringing together all affected within a community of Tender Loving Care. Some of the less rare leukodystrophies already have established and reputable support groups and, where applicable, we have signposted to these organisations and endeavour to work in partnership with them.

Other processes affecting white matter

Many different processes can affect the white matter e.g. trauma, infection, drug abuse, vascular disease. These conditions are not leukodystrophies. Similarly, acquired demyelination such as that which occurs in Multiple Sclerosis and similar conditions is not regarded as a leukodystrophy. Another word that is often used in medical literature when discussing white matter diseases is “leukoencephalopathy”. This simply means abnormal white matter in the brain and does not imply a genetic cause.

Common confusions

Sometimes the same disease is referred to as a leukodystrophy and a leukoencephalopathy e.g. adult onset autosomal dominant leukodystrophy (ADLD) can also be referred to as autosomal dominant late-onset leukoencephalopathy. Due to this terminology, there is often confusion surrounding what is and is not a leukodystrophy. As such there is no universally-agreed definition within the medical profession.

For the purposes of clarifying the conditions supported by Alex TLC, our definition of leukodystrophy is based on those conditions classified as inherited or genetic. This remit is based on guidance from UK specialists in paediatric and adult Inherited White Matter Disorders alongside three clinical papers: